Dr. Randy Schatzman On Dodging Disruption: The New Fundraising Norm Business of Biotech Podcast
About Andrea Tu
This author has yet to write their bio.
Meanwhile lets just say that we are proud Andrea Tu contributed a whooping 46 entries.
Bolt Biotherapeutics Presents BDC-1001 Ongoing Clinical Trial Design and Supportive Preclinical Data at Society for Immunotherapy of Cancer Annual Meeting
Bolt Biotherapeutics Closes $93.5 Million Series C Financing
CMC Considerations For In-Human Studies with Drs. Edith Perez and Nathan Ihle Business of Biotech Podcast
Randy Schatzman, PhD, CEO of Bolt Biotherapeutics Biotech 2050 Podcast
Bolt Bio Adds $93.5M to Move Ahead Immune-Stimulating Cancer Drugs Xconomy
Piramal Pharma Solutions and Bolt Biotherapeutics Sign Production Agreement ADC Review
U.S. Patent for Bolt Biotherapeutics’ Boltbody™ ISAC Platform Technology is a Major Milestone in the Development of BDC-1001 ADC Review
Randall Schatzman, Ph.D. to Lead Growth of Immune- Stimulating Antibody Conjugates at Bolt Biotherapeutics ADC Review
You acknowledge that the personal information you provide to Bolt Biotherapeutics will be processed to respond to your request or inquiry. For more information, please review our Privacy Notice .